Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05923008




Registration number
NCT05923008
Ethics application status
Date submitted
19/06/2023
Date registered
28/06/2023
Date last updated
29/11/2023

Titles & IDs
Public title
A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Scientific title
A Phase 1/2, Multicenter, Open-label Study of IBI130 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Secondary ID [1] 0 0
CIBI130A101
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Solid Tumor 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - IBI130

Experimental: IBI130 - IBI130


Treatment: Drugs: IBI130
Subjects will receive IBI130 until unacceptable toxicity, disease progression, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or for a maximum of 24 months of treatment, whichever occurs first.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Adverse events (AEs)
Timepoint [1] 0 0
Up to 30 days post last dose
Secondary outcome [1] 0 0
objective response rate (ORR)
Timepoint [1] 0 0
Time from first dose to best response to treatment, assessed up to 3 years
Secondary outcome [2] 0 0
duration of response(DoR)
Timepoint [2] 0 0
Duration of response from the first documentation of objective response (confirmed CR or PR) to the first documented disease progression, assessed up to 3 years
Secondary outcome [3] 0 0
overall survival (OS)
Timepoint [3] 0 0
Time from first dose to death, assessed up to 3 years

Eligibility
Key inclusion criteria
1. Subjects with the ability to understand and give written informed consent for
participation in this trial, including all evaluations and procedures as specified by
this protocol;

2. Male or female subjects = 18 years old;

3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1;

4. Anticipated life expectancy of = 12 weeks;

5. Adequate bone marrow and organ function
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Enrolled in any other interventional clinical research except unless only involved in
an observational study (non-interventional) or in the follow-up phase of an
interventional study;

2. Received previous anti-tumor therapy within 4 weeks or 5 half-lives of the anti-tumor
regimens before the first administration of study drug, whichever is shorter;

3. Plan to receive other antitumor therapy during the study excluding palliative
radiotherapy for the purpose of symptom (like pain) relief that must also do not have
impact on tumor assessment throughout the study;

4. Received live vaccines within 4 weeks prior to first administration of the study drug
or plan on receiving any live vaccine during the study;

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1/Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
14/11/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
31/10/2026
Actual
Sample size
Target
182
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment hospital [1] 0 0
Sunshine Coast University - Birtinya
Recruitment postcode(s) [1] 0 0
4575 - Birtinya

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Innovent Biologics (Suzhou) Co. Ltd.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a phase 1/2 multicenter, open-label, first-in-human study of IBI130. It includes a
phase 1 dose escalation and expansion section to identify MTD/RP2D of IBI130, plan to enroll
20~182 subjects,and a phase 2 to explore efficacy, safety and tolerability of IBI130 at RP2D
in specified types of solid tumor.Approximately 150 evaluable subjects will be enrolled for
phase 2.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05923008
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Serena Dong
Address 0 0
Country 0 0
Phone 0 0
0512 69566088
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05923008